<DOC>
	<DOCNO>NCT02875002</DOCNO>
	<brief_summary>This phase 1 , multicenter , open-label study design find RP2D volasertib , PLK1 inhibitor , belinostat , HDAC inhibitor , give combination patient relapse refractory B-cell T-cell lymphoma . A standard 3+3 dose-escalation design employ study enrollment begin dose level 1 .</brief_summary>
	<brief_title>Study Volasertib Belinostat Patients With Relapsed Refractory Aggressive B-cell T-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>A patient must meet follow inclusion criterion eligible participate study . Histologically confirm aggressive Bcell Tcell lymphoma include follow : Bcell lymphomas DLBCL ( include transform follicular lymphoma ) Mantle cell lymphoma Burkitt lymphoma Peripheral Tcell lymphoma ( PTCL ) exclude cutaneous Tcell lymphoma Disease relapse refractory minimum 2 previous therapy , Bcell lymphoma , minimum 1 previous therapy , PTCL For patient autologous stem cell transplant , disease relapse must 100 day follow transplant . For patient allogeneic stem cell transplant , follow condition must meet : ≥ 6 month since allogeneic transplant Graft vs. host disease ( GVHD ) present Patient currently immunosuppressive therapy At least one site measurable disease PET/CT : node measurable 2 diameter longest diameter &gt; 1.5cm extranodal lesion measurable 2 diameter longest diameter &gt; 1cm . Age ≥ 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ( see Appendix 1 ) Life expectancy least 3 month CBC differential provide evidence adequate bone marrow function define : Absolute neutrophil count ( ANC ) ≥ 1500/mm3 without growth factor support 7 day Platelets ≥ 75,000/mm3 ( without transfusion 7 day ) Adequate renal function define : Creatinine ≤ 1.5 x upper limit normal ( ULN ) calculate actual creatinine clearance ≥ 60 mL/min ( see Appendix 2 Cockcroft Gault Formula calculate creatinine clearance ) Adequate hepatic function define : AST ≤ 2.5 x ULN ALT ≤ 2.5 x ULN Total bilirubin ≤ 1.5 mg/dL Note : Patients document Gilbert 's syndrome eligible total bilirubin ≤ 3.0 mg/dL . Serum potassium serum magnesium within normal limit Note : Electrolytes may correct supplementation . For woman childbearing potential ( WCBP ) , negative serum pregnancy test perform within 14 day prior study enrollment ( 7 day prior initiation study treatment ) Note : WCBP define woman hysterectomy bilateral oophorectomy postmenopausal ( i.e. , menses precede 24 consecutive month ) WCBP male patient must agree use highly effective method birth control duration study treatment 6 month follow completion study treatment Note : A highly effective method contraception define one result low failure rate ( i.e . le 1 % per year ) use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomise partner . Ability understand willingness sign write informed consent document A patient meet follow exclusion criterion ineligible participate study . Any investigational treatment within 30 day prior initiation study treatment Plans concurrent treatment investigational agent Plans concurrent cancer treatment include steroid cancer control Chemotherapy large field radiotherapy within 3 week prior initiation study treatment Previous histone deacetylase inhibitor administer cancer treatment . History brain metastasis include leptomeningeal metastasis QTc interval ≥450 ( i.e. , ≥ grade 0 , per CTCAE version 4 ) ECG prior initiation study treatment . If baseline QTc screen ECG ≥ 450 m ( i.e. , ≥ grade 1 ) Check potassium magnesium serum level Correct identify hypokalemia and/or hypomagnesemia repeat ECG confirm QTc interval For patient baseline HR &lt; 60 &gt; 100 bpm , manual read QT cardiologist require , Fridericia correction apply determine QTcF interval . Note : For patient HR 60100 bpm , manual read QTc require . Any following related risk torsades de pointes sudden cardiac death : History sustain ventricular tachycardia ( VT , ventricular fibrillation ( VF ) , torsades de pointes , resuscitate cardiac arrest unless currently address implant cardiac defibrillator Concomitant treatment antiarrhythmic agent prevent control arrhythmia . Agents use ratecontrol atrial fibrillation permit provide prohibit due potential drug interaction ( see Section 6.4 ) Known congenital long QT syndrome Second degree atrioventricular ( AV ) block type II , third degree AV block , ventricular rate &lt; 50 bpm Any follow related ischemic heart disease : Angina ordinary physical activity Note : If angina occurs strenuous , rapid , prolonged exertion , patient eligible . Myocardial infarction within 6 month prior study enrollment Note : If myocardial infarction occur within 612 month prior study enrollment , patient must asymptomatic negative cardiac risk assessment ( e.g. , treadmill stress test , nuclear medicine stress test , stress echocardiogram ) ECG evidence cardiac ischemia ( i.e. , ST depression ≥ 2 mm , measure isoelectric line ST segment ; Twave inversion ≥ 4 mm measure isoelectric line peak Twave ) Any follow related heart failure : New York Heart Association ( NYHA ) class II , III IV congestive heart failure ( see Appendix 3 ) know leave ventricular ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram MRI Known hypertrophic cardiomegaly restrictive cardiomyopathy Clinically significant infection include active hepatitis B hepatitis C require treatment Known human immunodeficiency virus ( HIV ) seropositivity nNote : HIV test required History allergic reaction attribute compound similar chemical biologic composition belinostat volasertib History another primary malignancy , exclude nonmelanoma skin cancer , cervical carcinoma situ , and/or situ cancer treat local excision , remission least 2 year Pregnancy breastfeed Medical , psychological , social condition , opinion investigator , may increase patient 's risk , interfere patient 's participation study , hind evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>